

Reprinted from

# Immunopharmacology

---

Immunopharmacology 41 (1999) 183–186

## Effect of MSC on the immune response of mice

Máté Hidvégi <sup>a,b,\*</sup>, Erzsébet Rásó <sup>c</sup>, Rita Tömösközi Farkas <sup>a,d</sup>, Károly Lapis <sup>c</sup>,  
Béla Szende <sup>c</sup>

<sup>a</sup> *Birochem, Csanády u. 25 / A, Budapest H-1132, Hungary*

<sup>b</sup> *Department of Biochemistry and Food Technology, Technical University of Budapest, Műegyetem rkp. 3, Budapest H-1111, Hungary*

<sup>c</sup> *First Institute of Pathology and Experimental Cancer Research, Semmelweis University of Medicine, Üllői út 26, Budapest H-1085,  
Hungary*

<sup>d</sup> *Central Food Research Institute, Herman Ottó út 15, Budapest H-1022, Hungary*

Received 5 May 1998; received in revised form 17 December 1998; accepted 22 December 1998



ELSEVIER

## Aims and Scope

**Immunopharmacology** is a primary vehicle for swift publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, and toxicology. Review articles that encompass these subjects are also welcomed and will be featured.

The subject material appropriate for submission includes:

pharmacological compounds, microbial products and toxicological agents which affect the lymphoid system, and their mechanisms of action; agents which activate genes or modify transcription and translation; substances which improve or are involved in causing carcinoma, autoimmune diseases and immunological deficiencies; substances released through immunologic or related pathways that are pharmacologically active; production and function of cytokines and their receptors; other cell-derived factors that modify the immune system causing cytotoxicity, producing antibodies and mediating inflammatory responses; **immunotherapy and immunotoxicology contributions not covered by the above.**

Submissions may be sent directly to any of the Editors listed. The various special field(s) of each Editor are provided as a guide, particularly to help expedite the reviewing process.

## Editors

**T.E. Hugli**, (Editor-in-Chief), Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, U.S.A. Tel: +1 619 784 8158; fax: +1 619 784 8307; e-mail: hugli@scripps.edu

**F.L. Pearce**, Department of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, U.K. Tel: +44 (171) 387 7050; fax: +44 (171) 380 7463; e-mail: f.l.pearce@ucl.ac.uk

**K. Takatsu**, Department of Immunology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. Tel: +81 3 5449 5260, fax: +81 3 5449 5407; e-mail: takatsuk@ims.u-tokyo.ac.jp

## Editor Emeritus

**J.R. Battisto**

## Special Field

complement,  
immunomodulation,  
cell activation mediators

inflammatory cells,  
signal transduction

cytokines;  
parasitological diseases

## Editorial Board

**A.C. Allison**, Belmont, CA, USA (1999)

**I. Azuma**, Sapporo, Japan (2000)

**P. Borgeat**, Ste-Foy, PQ, Canada (2001)

**K.A. Brown**, London, UK (1998)

**M. Cathcart**, Cleveland, OH, USA (1998)

**B. Chain**, London, UK (1998)

**M. Ennis**, Belfast, UK (2001)

**R.L. Fairchild**, Cleveland, OH, USA (1999)

**J. Finke**, Cleveland, OH, USA (1998)

**F.A. Fitzpatrick**, Kalamazoo, MI, USA (1999)

**W.R. Green**, Lebanon, NH, USA (1999)

**E.A. Grimm**, Houston, TX, USA (1998)

**A. Hamblin**, London, UK (1998)

**T.A. Hamilton**, Cleveland, OH, USA (1998)

**T. Hirano**, Osaka, Japan

**M.P. Holsapple**, Midland, MI, USA (1998)

**B.T. Huber**, Boston, MA, USA (1999)

**M. Ishizuka**, Shizuoka, Japan (1999)

**F. Marceau**, Quebec, PQ, Canada (2001)

**D. Metcalf**, Melbourne, Australia (1998)

**E.L. Morgan**, La Jolla, CA, USA (1999)

**G.R. Nemerow**, La Jolla, CA, USA (1999)

**D.J. Noonan**, Lexington, KY, USA (1999)

**C.G. Orosz**, Columbus, OH, USA (1998)

**C.P. Page**, London, UK (1998)

**P.T. Peachell**, Sheffield, UK (2001)

**N. Ponzio**, Newark, NJ, USA (2001)

**J. Schmidt**, Frankfurt am Main, Germany (1999)

**J.R. Snyman**, Pretoria, South Africa

**G. Sturman**, London, UK (2001)

**G.O. Till**, Ann Arbor, MI, USA (2001)

**G. Trinchieri**, Philadelphia, PA, USA (1998)

**V.K. Tuohy**, Cleveland, OH, USA (1999)

**J. M. Wang**, San Diego, CA, USA (2001)

**T. Yoshida**, Ibaraki-ken, Japan (1999)

## Publication Information

*Immunopharmacology* (ISSN 0162-3109). For 1999 volumes 42–45 are scheduled for publication. Subscription prices are available upon request from the Publisher. Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by surface mail except to the following countries where air delivery via SAL mail is ensured: Argentina, Australia, Brazil, Canada, Hong Kong, India, Israel, Japan, Malaysia, Mexico, New Zealand, Pakistan, PR China, Singapore, South Africa, South Korea, Taiwan, Thailand, USA. For all other countries airmail rates are available upon request. Claims for missing issues must be made within six months of our publication (mailing) date.

**Advertising information.** Advertising orders and enquiries can be sent to: **Europe and ROW:** Rachel Gresle-Farthing, Elsevier Science Ltd., Advertising Department, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) (1865) 843565; fax: (+44) (1865) 843976; e-mail: r.gresle-farthing@elsevier.co.uk. **USA and Canada:** Elsevier Science Inc., Mr Tino DeCarlo, 655 Avenue of the Americas, New York, NY 10010-5107, USA; phone: (+1) (212) 633 3815; fax: (+1) (212) 633 3820; e-mail: t.decarlo@elsevier.com. **Japan:** Elsevier Science Japan, Advertising Department, 9-15 Higashi-Azabu 1-chome, Minato-ku, Tokyo 106, Japan; phone: (+81) (3) 5561 5033; fax: (+81) (3) 5561 5047.

**Orders, claims, and product enquiries:** please contact the Customer Support Department at the Regional Sales Office nearest you:

**New York:** Elsevier Science, P.O. Box 945, New York, NY 10159-0945, USA; phone: (+1) (212) 633 3730, [toll free number for North American customers: 1-888-4ES-INFO (437-4636)]; fax: (+1) (212) 633 3680; e-mail: usinfo-f@elsevier.com

**Amsterdam:** Elsevier Science, P.O. Box 211, 1000 AE Amsterdam, The Netherlands; phone: (+31) 20 485 3757; fax: (+31) 20 485 3432; e-mail: nlinfo-f@elsevier.nl

**Tokyo:** Elsevier Science, 9-15, Higashi-Azabu 1-chome, Minato-ku, Tokyo 106, Japan; phone: (+81) (3) 5561 5033; fax: (+81) (3) 5561 5047; e-mail: info@elsevier.co.jp

**Singapore:** Elsevier Science, No. 1 Temasek Avenue, #17-01 Millenia Tower, Singapore 039192; phone: (+65) 434 3727; fax: (+65) 337 2230; e-mail: asiainfo@elsevier.com.sg

**Rio de Janeiro:** Elsevier Science, Rua Sete de Setembro 111/16 Andar, 20050-002 Centro, Rio de Janeiro - RJ, Brazil; phone: (+55) (21) 509 5340; fax: (+55) (21) 507 1991; e-mail: elsevier@campus.com.br [Note (Latin America): for orders, claims and help desk information, please contact the Regional Sales Office in New York as listed above]

© 1999, Elsevier Science B.V. All rights reserved.



ELSEVIER

Immunopharmacology 41 (1999) 183–186

Immunopharmacology

## Effect of MSC on the immune response of mice

Máté Hidvégi<sup>a,b,\*</sup>, Erzsébet Rásó<sup>c</sup>, Rita Tömösközi Farkas<sup>a,d</sup>, Károly Lapis<sup>c</sup>,  
Béla Szende<sup>c</sup>

<sup>a</sup> *Birochem, Csanády u. 25 / A, Budapest H-1132, Hungary*

<sup>b</sup> *Department of Biochemistry and Food Technology, Technical University of Budapest, Műegyetem rkp. 3, Budapest H-1111, Hungary*

<sup>c</sup> *First Institute of Pathology and Experimental Cancer Research, Semmelweis University of Medicine, Üllői út 26, Budapest H-1085, Hungary*

<sup>d</sup> *Central Food Research Institute, Herman Ottó út 15, Budapest H-1022, Hungary*

Received 5 May 1998; received in revised form 17 December 1998; accepted 22 December 1998

### Abstract

The supposed immunostimulatory actions of MSC, a new fermented wheat germ extract standardized to its benzoquinone composition (trade name: AVEMAR) were studied examining blastic transformation of peripheral blood lymphocytes of mice treated with MSC. It was found that MSC significantly increased the degree of blastic transformation caused by Concanavalin A. Using the B<sub>10</sub>LP to C<sub>57</sub>B1 skin graft system, MSC (0.03 and 3.0 g kg<sup>-1</sup> applied orally) acted in favour of restoring the immune function. On the other hand, 2,6-dimethoxy-*p*-benzoquinone (DMBQ), applied in equivalent doses (0.012 and 1.2 mg kg<sup>-1</sup>), did not shorten the rejection time of skin grafts. The immune restoring effect, as well as the blastic transformation enhancing potential of MSC may be exploited in various cases of decreased immune response. © 1999 Elsevier Science B.V. All rights reserved.

**Keywords:** Fermented wheat germ extract; Benzoquinones; AVEMAR; Lymphocytes; Blastic transformation; Skin graft; Immune reconstruction

### 1. Introduction

According to Pethig et al. (1983), growth inhibition of Ehrlich ascites tumor can be achieved by treatment of the tumor-bearing mice with a mixture of 2,6-dimethoxy-*p*-benzoquinone (DMBQ) and ascorbic acid. This mixture produces long-lived semiquinone and ascorbic free radicals. Vitamin C is

present in many plants, while DMBQ in wheat germ. It has been shown that quenching of quinone and ascorbic radicals depends on an NAD(P)H-dependent SH group containing enzyme (Pethig et al., 1984). The cytotoxicity of the radical mixture was supposed to be associated with the decreased NAD(P) reducing capacity of tumor cells (Pethig et al., 1985). During the fermentation of wheat germ with yeast, quinones are released by the glycosidase enzyme of the yeast fungus. The original perception of Szent-Györgyi (1982) was that by means of the biological activity of these released quinones, the fermented wheat germ may possess immunostimulatory effect.

\* Corresponding author. Tel.: +36-209-146-222; fax: +36-1-339-4244; e-mail: birochem@mail.datanet.hu

Based on the studies of Szent-Györgyi, a dried, standardized extract of wheat germ fermented by *Saccharomyces cerevisiae* was produced. The fermentation process had previously been optimized to yield  $0.4 \text{ mg g}^{-1}$  (on dry matter basis) concentration of DMBQ in the extract. The dried extract, named MSC (trade name: AVEMAR) was administered to mice. Taking into consideration (a) the DMBQ content of MSC, (b) the DMBQ dose applied by Pethig et al. (1983) resulting in complete retraction of Ehrlich ascites tumor in mice, (c) solubility and/or suspendability of MSC in water, and (d) the size of the volume which can be injected into a mice via gastric tube,  $3 \text{ g kg}^{-1}$  was chosen as the daily intake dose. The aim of our experiments was to examine the effect of this agent on blastic transformation of peripheral blood lymphocytes in the treated animals, and also to try to influence the rejection period of skin grafts.

## 2. Material and methods

### 2.1. Preparation of MSC

Seventy kilograms *S. cerevisiae*, obtained from a local grain distillers company, was suspended into a  $3 \text{ m}^3$  isothermic ( $30 \pm 1^\circ\text{C}$ ) fermentor containing  $2 \text{ m}^3$  of tap water. After mixing, 210 kg of freshly ground wheat germ, obtained from a local grain milling company, was added to the yeast suspension. The mixture was then fermented, filtered, concentrated and spray-dried. The resulted pulver was homogenized and kept in sealed containers.

### 2.2. Treatment of mice for lymphocyte proliferation assay

$\text{C}_{57}\text{B1}/6$  mice (8 weeks old  $20 \pm 2 \text{ g}$  weighing males) were treated orally, via gastric tube, as aliquots of 0.1 ml, five times a week for 6 weeks as follows:

1. Group 1: untreated control
2. Group 2: control, given 0.1 ml of tap water
3. Group 3: treated with  $3 \text{ g kg}^{-1}$  MSC.

Cells obtained from perfused spleen of  $\text{C}_{57}\text{B1}/6$  mice were suspended in RPMI tissue culture medium

(Sigma) supplemented with 10% heat inactivated fetal calf serum (Sigma), 2 nM L-glutamine (Gibco) and  $100 \mu\text{g ml}^{-1}$  gentamicin (Sigma). A total of  $5 \times 10^4$  spleen cells in  $200 \mu\text{l}$  medium were placed in each well of a flat-bottomed 96-well microplate (Costar) using five parallel samples. Concanavalin A (Con A, Pharmacia) ( $1 \mu\text{g ml}^{-1}$ ) was added to the cell suspensions. Control cultures without lectin were also included. The plates were incubated at  $37^\circ\text{C}$  in a humidified atmosphere with 5%  $\text{CO}_2$  for 72 h. The cultures were pulse labelled with  $0.4 \mu\text{Ci } ^3\text{H}$ -thymidine (Sigma) 24 h before termination. The cells were harvested on filter paper disks by an automated sample harvester (Skatron). Isotope determinations were made in a liquid scintillation counter (Beckman). The results were expressed in cycles per minute using the arithmetic mean of five replicate values.

### 2.3. Animals for skin graft

Eight weeks old ( $20 \pm 2 \text{ g}$ ) inbred  $\text{C}_{57}\text{B1}_{10}$  female and male mice were used as recipients in the skin graft experiments. The donors were 8 weeks old ( $20 \pm 2 \text{ g}$ ) inbred  $\text{B}_{10}\text{LP}$  female and male mice. The animals were kept in plastic cages (five per cage), fed with standard rodent food pellets (LATI, Gödöllő, Hungary) and given tap water ad libitum. The room temperature was  $22 \pm 2^\circ\text{C}$ , the relative humidity was  $50 \pm 5\%$ .

### 2.4. Thymectomy

Suction thymectomy was performed at the age of 8 weeks, as described by Kopper and Steel (1975).

### 2.5. Anaesthesia

All interventions were performed under Nembutal (Jenapharm, Germany) anaesthesia ( $70 \text{ mg kg}^{-1}$  i.p.).

### 2.6. Skin graft

Ear skin of  $\text{B}_{10}\text{LP}$  mice was grafted onto the dorsal skin of  $\text{C}_{57}\text{B1}_{10}$  mice, 7 weeks after thymectomy. The grafts were fixed with plaster of Paris bandage. The bandage was removed 7 days after grafting.

Table 1  
The effect of MSC on the lymphoblastic transformation of mouse spleen cells ( $^3\text{H}$ -thymidine incorporation)

Treatment	0 $\mu\text{g ml}^{-1}$ Con A		1 $\mu\text{g ml}^{-1}$ Con A	
	Mean (cpm)	SEM	Mean (cpm)	SEM
Control—untreated	194.9	36.0	3760.6	583.3
Control—water	397.1	52.0	5910.9	677.1
MSC	443.4	101.9	8041.8	957.1

### 2.7. Follow-up of rejection

The mice were inspected daily after removing the bandage. Animals losing the graft with the removal of the plaster of Paris were considered as technical failures. The day of rejection was defined as the day when the first crustation of the graft occurred and when this initial reaction was intensified on the following days.

The time of skin graft rejection of each animal was registered, up to 63 days after the removal of the bandage.

### 2.8. Experimental groups: ( $n = 10$ / group)

#### 2.8.1. Experiment I

1. Control females (given 0.1 ml of tap water via gastric tube, five times a week)
2. Control males (given 0.1 ml of tap water via gastric tube, five times a week)
3. Thymectomized females (given 0.1 ml of tap water via gastric tube, five times a week)
4. Thymectomized males (given 0.1 ml of tap water via gastric tube, five times a week)
5. Thymectomized females treated with a 100-fold dilution of 3 g  $\text{kg}^{-1}$  MSC, given as aliquots of 0.1 ml, via gastric tube, five times a week.
6. Thymectomized males treated with 0.03 g  $\text{kg}^{-1}$  MSC, given as aliquots of 0.1 ml, via gastric tube, five times a week.

#### 2.8.2. Experiment II

1. Thymectomized males (given 0.1 ml of tap water via gastric tube, five times a week)
2. Thymectomized males treated with 3.0 g  $\text{kg}^{-1}$  MSC given as aliquots of 0.1 ml, via gastric tube, five times a week

3. Thymectomized males treated with 0.03 g  $\text{kg}^{-1}$  MSC given as aliquots of 0.1 ml, via gastric tube, five times a week
4. Thymectomized males treated with 1.2 mg  $\text{kg}^{-1}$  DMBQ (equivalent to 3 g  $\text{kg}^{-1}$  MSC), in aliquots of 0.1 ml, via gastric tube, five times a week
5. Thymectomized males treated with 0.012 mg  $\text{kg}^{-1}$  DMBQ (equivalent to 0.03 g  $\text{kg}^{-1}$  MSC), in aliquots of 0.1 ml, via gastric tube, five times a week.

## 3. Results

### 3.1. Effect of MSC on the blastic transformation of lymphocytes

The results are shown in Table 1. Con A treatment of the cell cultures caused significant increase in  $^3\text{H}$ -thymidine incorporation into the splenic cells. The increase was highest in the cultures obtained from the MSC-treated mice.

### 3.2. Effect of MSC on skin graft survival

Table 2 shows the survival times of skin grafts in the various groups of Experiment I. Untreated (only saline) non-thymectomized  $\text{C}_{57}\text{B}_{10}$  mice rejected the skin of  $\text{B}_{10}\text{LP}$  mice significantly earlier [males 21.0 (SEM: 3.1), females 28.7 (SEM: 4.5) days] than thymectomized  $\text{C}_{57}\text{B}_{10}$  mice [males 52.4 (SEM: 5.0), females 41.6 (SEM: 5.5) days]. When thymectomized mice were treated with MSC, the graft survival times were significantly shorter than in the case of the untreated thymectomized mice [males 28.8 (SEM: 8.6), females 32.6 (SEM: 4.5) days], but

Table 2  
Effect of MSC on skin graft rejection in mice (Experiment I)

Treatment	Male		Female	
	Mean (days)	SEM	Mean (days)	SEM
Control <sup>a</sup>	21.0	3.1	28.7	4.5
Control	52.4	5.0	41.6	5.5
MSC (0.03 g $\text{kg}^{-1}$ )	28.8**	8.6	32.6***	4.5

<sup>a</sup>Without thymectomy.

\*\* 0.001 <  $p$  < 0.01 paired  $t$ -test.

\*\*\* 0.01 <  $p$  < 0.05 paired  $t$ -test.

Table 3  
Effect of MSC and DMBQ on skin graft rejection in male mice (Experiment II)

Treatment	Mean (days)	SEM
Control	48.0	3.2
MSC (3 g kg <sup>-1</sup> )	26.4*	4.2
MSC (0.03 g kg <sup>-1</sup> )	27.8*	4.8
DMBQ (1.2 mg kg <sup>-1</sup> )	58.5	5.0
DMBQ (0.012 mg kg <sup>-1</sup> )	49.1	4.5

\* 0.001 < *p* < 0.01 paired *t*-test vs. control.

did not reach the values of non-thymectomized untreated mice.

Table 3 shows the results of Experiment II. MSC, both in 3.0 g kg<sup>-1</sup> and 0.03 g kg<sup>-1</sup> doses, considerably shortened the survival time of skin grafts, as compared to the control. The low dose of DMBQ (0.012 mg kg<sup>-1</sup> day<sup>-1</sup>) did not exert any effect on the skin grafts, but the higher dose (1.2 mg kg<sup>-1</sup>) elongated the graft survival. Moreover, the 1.2 mg kg<sup>-1</sup> day<sup>-1</sup> oral DMBQ treatment proved to be toxic, as five animals died in the course of the experiment.

#### 4. Discussion

Our *in vitro* results show that MSC (AVEMAR) pre-treatment of mice increases the blastic transformation inducing effect of Con A on peripheral T lymphocytes. As the stimulatory effect on lymphocytes was exerted by *in vivo* treatment, the relatively moderate augmentation of lymphoblast transformation may be considered as important.

The inbred mouse strain B<sub>10</sub>LP is a co-isogenic substrain of C<sub>57</sub>B1 mice. A so-called weak histocompatibility exists between these two strains. This means that rejection of the skin grafts occurs 16–25 days after transplantation (Taylor and Lehrfeld, 1955; Snell and Bunker, 1964; Snell et al., 1967).

In accordance with our earlier results, the present experimental data show that thymectomy itself increased the period of survival of skin grafts. On the

other hand, MSC treatment resulted in a decrease of this period. Interestingly, this effect appeared at the daily dose of 0.03 g kg<sup>-1</sup> and remained the same even when the daily dose was increased to 3.0 g kg<sup>-1</sup>. On the other hand, DMBQ treatment proved ineffective at a dose equivalent to 0.03 g kg<sup>-1</sup> MSC, showing high toxicity and a moderate immune-depressive effect at a dose equivalent to 3.0 g kg<sup>-1</sup> MSC. Considering these results, DMBQ alone cannot be responsible for the immunostimulatory properties of MSC. It may be supposed that other substances present in the fermentation product of wheat germ exert the effect observed in our experiments.

From therapeutic point of view, the immunostimulatory and immune function reconstructing effects, as well as blastic transformation enhancing potential of MSC (AVEMAR), may be exploited in various cases of decreased immune response.

#### References

- Kopper, L., Steel, G.G., 1975. The therapeutic response of three human tumor lines maintained in immune-suppressed mice. *Cancer Res.* 35, 2704–2713.
- Pethig, R., Gascoyne, P.R.C., McLaughlin, J.A., Szent-Györgyi, A., 1983. Ascorbate–quinone interactions: electrochemical, free radical, and cytotoxic properties. *Proc. Natl. Acad. Sci. U.S.A.* 80, 129.
- Pethig, R., Gascoyne, P.R.C., McLaughlin, J.A., Szent-Györgyi, A., 1984. Interaction of the 2,6-dimethoxysemiquinone and ascorbyl free radicals with Erlich ascites cells: a probe of cell-surface charge. *Proc. Natl. Acad. Sci. U.S.A.* 81, 2088.
- Pethig, R., Gascoyne, P.R.C., McLaughlin, J.A., Szent-Györgyi, A., 1985. Enzyme-controlled scavenging of ascorbyl and 2,6-dimethoxysemiquinone free radicals in Erlich ascites tumor cells. *Proc. Natl. Acad. Sci. U.S.A.* 82, 1439.
- Snell, G.D., Bunker, H.P., 1964. Histocompatibility genes of mice: IV. The position of H-3 in the fifth linkage group. *Transplantation* 2, 743.
- Snell, G.D., Gudkowitz, G., Bunker, H.P., 1967. Histocompatibility genes of mice: VII. H-13. A new histocompatibility locus in the fifth linkage group. *Transplantation* 5, 492.
- Szent-Györgyi, A., 1982. Biological oxidation and cancer. *Int. J. Quant. Chem. Quant. Biol. Symp.* 9, 27.
- Taylor, A.C., Lehrfeld, J.W., 1955. Definition of survival time of homografts. *Ann. NY Acad. Sci.* 59, 351.

**Instructions to Authors** These instructions can also be found on the World Wide Web: access under <http://www.elsevier.nl> or <http://www.elsevier.com>

#### **Submission and Prior Publication**

Submission of a manuscript to **Immunopharmacology** implies the transfer of copyright from the author to the Publisher, and that the data has not been published elsewhere and is not or will not be submitted to another journal for publication while the manuscript is under review by **Immunopharmacology**. An abstract or oral presentation of the data is not considered a prior publication. However, any duplication of tables, figures, and summaries of data and/or results that are in print, or submitted elsewhere for print, must be acknowledged in the manuscript and copyright clearance provided.

Authors must submit one original and two copies of the complete manuscript and must follow the format and style described later in these "Instructions to Authors". All submissions must be accompanied by a covering letter affirming that the manuscript is original work and that all authors named on the title page must have agreed to the submission of the manuscript and agree that if the manuscript is accepted for publication in **Immunopharmacology**, it will not be published again in the same form, in any language, without the prior consent of the Publisher: Elsevier Science B.V., Copyright and Permissions Department, PO Box 521, 1000 AM Amsterdam, The Netherlands.

The authors may suggest reviewers who are competent in the field, or indicate individuals who should not be asked to provide an evaluation of the work. The Editors will take these author recommendations seriously, but it is the Editors final decision as to who will be used as reviewers of a particular submission.

#### **Manuscript preparation**

Manuscripts of full-length articles or short communications providing a brief but complete account of a particular study should be submitted to the Editor-in Chief or either Associate Editor (for addresses see front cover). The preferred medium of final submission to the accepting editor is on disk with accompanying reviewed and revised manuscript (see "Electronic manuscripts" below). Manuscripts should be typed in triplicate, in English, double-spaced, on one side of the paper only and divided into Introduction, Materials and Methods, Results and Discussion. An abstract of not more than 200 words should accompany full-length articles; and 3–6 keywords or phrases should be provided for indexing purposes. On a separate page, list and define all abbreviations (excluding units of measure) that are used in the text. The title page should include the authors' full names and professional addresses and the complete address of the corresponding author. References, tables and figure legends should be typed on separate sheets. Authors are requested to follow the IUPHAR Guidelines for Classification of New Receptor Subtypes (see *Immunopharmacology*, Vol. 30, p. 189 or p. 255). **Authors in Japan please note:** Upon request, Elsevier Science Japan will provide authors with a list of people who can check and improve the English of their paper (*before submission*). Please contact our Tokyo office: Elsevier Science Japan, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044; Tel. (03)-5561-5032; Fax (03)-5561-5045.

**Tables** should be typed on separate sheets with double spacing, numbered consecutively with Roman numerals, and should not contain vertical lines. A short descriptive title should appear above each table, with any explanations or footnotes (identified with a, b, c, etc.) below.

**Figures** must be suitable for high-quality reproduction. Line drawings should be in India ink on drawing or tracing paper, or be sharp, well-contrasting prints on glossy paper suitable for immediate reproduction. Lettering should be complete, of professional quality, and of an appropriate size: where necessary, a scale bar should be included. Figures should be designed to fit a single column (7.5 cm wide) or a double column (16 cm wide), and should be clearly marked on the back with the number, orientation and author's name. Figure legends should be typed double-spaced on a separate sheet. The cost of colour reproduction must be borne by the author(s).

**References** should be listed in alphabetical order. In the text, they should be referred to by name and year: if there are more than two authors, use the name of the first author followed by et al. Papers by the same author(s), published in the same year, should be distinguished by the use of lowercase letters following the date. Unpublished data, personal communications and papers in preparation or 'submitted' should not be listed in the References (but may be incorporated at the appropriate place in the text); work 'in press' may only be listed if it has been accepted for publication. References should be given in accordance with the following examples:

*Journal:* Lundberg, C., Marceau, F., Huey, R., Hugli, T.E., 1986. Anaphylatoxin C5a fails to promote prostacyclin release in cultured endothelial cells from human umbilical veins. *Immunopharmacology* 12, 135–143.

*Monograph:* Descotes, J., 1986. *Immunotoxicology of Drugs and Chemicals*. Elsevier, Amsterdam.

*Contributed volume:* Talal, N., Hadden, J.W., 1985. Hormones, immunomodulating drugs and autoimmunity. In: Bonta, I.L., Bray, M.A., Parnham, M.J. (Eds.), *The Pharmacology of Inflammation*. Elsevier, Amsterdam, pp. 355–370.

*Electronic manuscripts:* Electronic manuscripts have the advantage that there is no need for the rekeying of text, thereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery of proofs. For the initial submission of manuscripts for consideration, hardcopies are sufficient. For the processing of *accepted papers*, electronic versions are preferred. After *final acceptance*, your disk plus one, final and exactly matching printed version should be submitted together. Double density (DD) or high density (HD) diskettes (3<sup>1</sup>/<sub>2</sub> or 5<sup>1</sup>/<sub>4</sub> inch) are acceptable. It is important that the file saved is in the native format of the wordprocessor program used. Label the disk with the name of the computer and wordprocessing package used, your name, and the name of the file on the disk. Further information may be obtained from the Publisher.

For questions concerning **accepted** papers (e.g. proofs, page numbers, publication date) please contact *Immunopharmacology*, Elsevier Science B.V., P.O. Box 2759, 1000 CT Amsterdam, The Netherlands. Tel.: +31-20-485-3435; fax: +31-20-485-2431; e-mail: [e.perrill@elsevier.nl](mailto:e.perrill@elsevier.nl)

#### **Proofs**

One set of proofs will be supplied for the author to check for typesetting accuracy, to be returned to the publisher within 3 days of receipt. No changes to the original manuscript will be allowed at this stage.

#### **Reprints**

Fifty free reprints per contribution will be supplied. An order form will be sent to the author enabling further reprints to be ordered at prices listed on the form.

**Immunopharmacology has no page charges**

Printed in The Netherlands

© The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).